The Ministry of Health would like to notify members of the public following reports in the newspaper and media on the withdrawal of the market authorisation of AstraZeneca's COVID-19, Vaxzevria in the European Union. The withdrawal of the market authorization of the vaccine cited from press and media reports was at the request of the manufacturer AstraZeneca itself.

From the reports, AstraZeneca requested on voluntary withdrawal of the market authorisation of Vaxzevria due to a decline in demand whereby the vaccine was initially developed to provide protection against the original variant (ancestral) COVID-19 only. 

In a notice on its website, the European Medicines Agency also announced of Vaxzevria withdrawal at the request of the market authorisation holder, AstraZeneca AB whereby The European Commission was informed of AstraZeneca's decision to permanently stop marketing Vaxzevria due to commercial reasons.

Vaxzevria is one of the COVID-19 vaccines that has been granted with the Emergency Use Authorisation by Brunei Darussalam Medicines Control Authority, BDMCA during COVID-19 pandemic. 

It was used in the National Vaccination Programme for COVID-19 in 2021. The validity of the Emergency Use Authorization for Vaxzevria in Brunei Darussalam was lapsed in July 2022. The Ministry of Health will continue to maintain its ongoing surveillance of pharmaceutical products and vaccines marketed in the country to ensure the safety and well-being of the public.

For further information and enquiries, contact the Talian Darussalam 123.

Source:
RTB NEWS

by RTB NEWS

If you have any stories or news that you would like to share with the global online community, please feel free to share it with us by contacting us directly at [email protected]